GlaxoSmithKline plc
(the '
Company
')
Conditional Share Awards and Shares withheld or sold to meet tax liabilities
This notification sets out details of the vesting of awards made in 2017 under the GlaxoSmithKline Share Value Plan and the subsequent sale of Ordinary Shares and American Depositary Shares ('ADSs') to meet tax liabilities arising on the vesting. The awards, which were conditional on continued employment with the GlaxoSmithKline group, vested on 17 February 2020 (for awards over Ordinary Shares) and 18 February 2020 (for awards over ADSs).
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms D Conrad |
|||
b) |
Position/status |
SVP, Human Resources |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The vesting of Ordinary Shares awarded in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
11,060 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms D Conrad |
|||
b) |
Position/status |
SVP, Human Resources |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Following the vesting of Ordinary Shares awarded in 2017 under the Company's Share Value Plan, Ms Conrad received a cash amount of £184,000 (less applicable tax withholding) which is equal to the market value of the number of Ordinary Shares which would otherwise have been transferred to her. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.619 |
11,060 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-18 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr J Ford |
|||
b) |
Position/status |
SVP & General Counsel |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
|||
b) |
Nature of the transaction |
The vesting of ADSs awarded in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$0.00 |
6,320 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-18 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr J Ford |
|||
b) |
Position/status |
SVP & General Counsel |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
|||
b) |
Nature of the transaction |
The sale of ADSs to meet tax liabilities on the vesting of awards granted in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$43.544 |
2,971 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-18 |
|||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms S Jackson |
|||
b) |
Position/status |
SVP, Global Communications & CEO Office |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The vesting of Ordinary Shares awarded in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
13,070 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms S Jackson |
|||
b) |
Position/status |
SVP, Global Communications & CEO Office |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.619 |
6,143 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr D Jackson |
|||
b) |
Position/status |
PCA of Ms S Jackson (SVP, Global Communications & CEO Office) |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The vesting of Ordinary Shares awarded in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
3,810 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr D Jackson |
|||
b) |
Position/status |
PCA of Ms S Jackson (SVP, Global Communications & CEO Office) |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.619 |
1,791 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr R Simard |
|||
b) |
Position/status |
President, Pharmaceuticals Supply Chain |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The vesting of Ordinary Shares awarded in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
11,060 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr R Simard |
|||
b) |
Position/status |
President, Pharmaceuticals Supply Chain |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.619 |
5,199 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms D Waterhouse |
|||
b) |
Position/status |
CEO of ViiV Healthcare |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The vesting of Ordinary Shares awarded in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
15,160 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms D Waterhouse |
|||
b) |
Position/status |
CEO of ViiV Healthcare |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.619 |
7,126 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms V Whyte |
|||
b) |
Position/status |
Company Secretary |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The vesting of Ordinary Shares awarded in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
11,060 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
N/A |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms V Whyte |
|||
b) |
Position/status |
Company Secretary |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2017 under the Company's Share Value Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.619 |
5,199 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-02-17 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |